Why Did the "Five-Year Incidence of Progression to Osteoarthritis and Total Joint Arthroplasty in Patients Prescribed Glucagon-Like Peptide 1 (GLP-1) Receptor Agonists" Differ From Previous Randomized Controlled Study?
Ng, Karman; Ellis, Ron; Mobasheri, Aliet al.
2024 • In Journal of Arthroplasty, 39 (12), p. 68 - e69
Mobasheri, Ali ; Université de Liège - ULiège > Département des sciences de la santé publique > Santé publique, Epidémiologie et Economie de la santé ; University of Oulu, Finland
Reginster, Jean-Yves ; Université de Liège - ULiège > Département des sciences de la santé publique ; King Saud University, Riyadh, Kingdom of Saudi Arabia
Language :
English
Title :
Why Did the "Five-Year Incidence of Progression to Osteoarthritis and Total Joint Arthroplasty in Patients Prescribed Glucagon-Like Peptide 1 (GLP-1) Receptor Agonists" Differ From Previous Randomized Controlled Study?
Azuri, J., Hammerman, A., Aboalhasan, E., Sluckis, B., Arbel, R., Liraglutide versus semaglutide for weight reduction—a cost needed to treat analysis. Obesity 31 (2023), 1510–1513, 10.1002/oby.23752.
Salis, Z., Sainsbury, A., Keen, H., Gallego, B., Jin, X., Weight loss is associated with reduced risk of knee and hip replacement: a survival analysis using Osteoarthritis Initiative data. Int J Obes 46 (2022), 874–884, 10.1038/s41366-021-01046-3.
Bliddal, H., Semaglutide 2.4mg efficacy and safety in people with obesity and knee osteoarthritis: results from the STEP 9 randomised clinical trial. Osteoarthritis Cartil 32 (2024), 745–746, 10.1016/j.joca.2024.03.003.
Zhu, H., Zhou, L., Wang, Q., Cai, Q., Yang, F., Jin, H., et al. Glucagon-like peptide-1 receptor agonists as a disease-modifying therapy for knee osteoarthritis mediated by weight loss: findings from the Shanghai Osteoarthritis Cohort. Ann Rheum Dis 82 (2023), 1218–1226, 10.1136/ard-2023-223845.
